Levant

Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership to advance personalised medicine and genomics

Retrieved on: 
Monday, June 19, 2023
BIO, Levant, Partnership, Senior, Multiple myeloma, Policy, The Department, Quality of life, ABU, Medicine, M42, Genomics, Research, Lung cancer, Translation, Pharmacotherapy, Innovation Center station, Department of Health (Abu Dhabi), AbbVie, Guideline, Memorandum of understanding, Diagnosis, Emirate, Doh, United Arab Emirates, Pharmaceutical industry

M42 is a first-of-its-kind, tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.

Key Points: 
  • M42 is a first-of-its-kind, tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.
  • The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.
  • As part of its preventive healthcare efforts, Abu Dhabi launched the region's first Personalised Precision Medicine Programme for oncology in 2022.
  • The programme integrates predictive, personalised and precision medicine using genomics to transform diagnostics, drug therapy and prevention and tailor it to the needs specific to individuals.

Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership to advance personalised medicine and genomics

Retrieved on: 
Monday, June 19, 2023
BIO, Levant, Partnership, Senior, Multiple myeloma, Policy, The Department, Quality of life, ABU, Medicine, M42, Genomics, Research, Lung cancer, Translation, Pharmacotherapy, Innovation Center station, Department of Health (Abu Dhabi), AbbVie, Guideline, Memorandum of understanding, Diagnosis, Emirate, Doh, United Arab Emirates, Pharmaceutical industry

M42 is a first-of-its-kind, tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.

Key Points: 
  • M42 is a first-of-its-kind, tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.
  • The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.
  • As part of its preventive healthcare efforts, Abu Dhabi launched the region's first Personalised Precision Medicine Programme for oncology in 2022.
  • The programme integrates predictive, personalised and precision medicine using genomics to transform diagnostics, drug therapy and prevention and tailor it to the needs specific to individuals.

US Senate Candidate Salem Supports Any Efforts by Israel to Defend Against Iranian Attacks

Retrieved on: 
Monday, August 2, 2021
Western Asia, Eurasia, Regions, Israel, Levant, Republics

Israel's Foreign Minister blames "Iranian terrorism" for an attack in the Arabian Sea that killed two people.

Key Points: 
  • Israel's Foreign Minister blames "Iranian terrorism" for an attack in the Arabian Sea that killed two people.
  • Salem, an Egyptian-American, stated, "The attack underscores an impending escalation of fighting due to human casualties in international waters.
  • Salem stressed, "It is time for President Biden and the United States military forces to establish a stronger presence in the Gulf.
  • Salem has a clear view of Middle East issues and is dedicated to informing Americans and the world-at-large of terrorist action against the State of Israel.

Spectral Medical Inc. Provides Tigris Clinical Trial Update

Retrieved on: 
Wednesday, July 28, 2021
Rivers of Asia, Health sciences, Rivers, Geography of Iraqi Kurdistan, Levant, Mesopotamia, Tur Abdin, Upper Mesopotamia, Clinical trial, Screening, Euphrates, Tigris

Our sites have aggressively increased activities around the Tigris trial, including heightened patient screening, enrollment, and randomization.

Key Points: 
  • Our sites have aggressively increased activities around the Tigris trial, including heightened patient screening, enrollment, and randomization.
  • We are also onboarding additional clinical trial sites, including the University of Michigan, which is now actively screening patients.
  • Chris Seto, CEO of Spectral, further noted, With a total of nineteen patients now randomized within the Tigris trial, we are pleased with the acceleration of trial activities and remain optimistic about the trial outcome.
  • We remain highly encouraged by the outlook for the Tigris trial based on the outcome of the earlier EUPHRATES trial.

Capture the Dazzling Colours of Eid Al Adha with the OPPO Reno5 Series'

Retrieved on: 
Thursday, July 15, 2021
Mobile phones, Smartphones, Adha, Oppo Reno, Eid

DUBAI, UAE, July 15, 2021 /PRNewswire/ -- As Eid Al Adha draws near, family and friends are preparing to capture the occasion's countless special moments.

Key Points: 
  • DUBAI, UAE, July 15, 2021 /PRNewswire/ -- As Eid Al Adha draws near, family and friends are preparing to capture the occasion's countless special moments.
  • "The Reno5 Seriesenables users to be the creators of their own Eid Al Adha moments" said Tarek Zaki, Senior Product Manager, Middle East and Africa at OPPO.
  • The photography expert in any scenario, AI-powered features in OPPO Reno5 Series smartphones allow users full control over their clicks.
  • OPPO's unwavering passion for innovation to benefit humankind comes to life with the OPPO Reno5 Series smartphones this Eid Al Adha.

Capture the Dazzling Colours of Eid Al Adha with the OPPO Reno5 Series'

Retrieved on: 
Thursday, July 15, 2021
Mobile phones, Smartphones, Adha, Oppo Reno, Eid

"The Reno5 Seriesenables users to be the creators of their own Eid Al Adha moments" said Tarek Zaki, Senior Product Manager, Middle East and Africa at OPPO.

Key Points: 
  • "The Reno5 Seriesenables users to be the creators of their own Eid Al Adha moments" said Tarek Zaki, Senior Product Manager, Middle East and Africa at OPPO.
  • "Now you can get as creative as you want with phenomenal Eid Al Adha photos and videos.
  • The photography expert in any scenario, AI-powered features in OPPO Reno5 Series smartphones allow users full control over their clicks.
  • OPPO's unwavering passion for innovation to benefit humankind comes to life with the OPPO Reno5 Series smartphones this Eid Al Adha.

Israel Construction Market Report 2021: Key Trends and Opportunities to 2025 - Latest News and Developments & Construction Projects Momentum Index - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Construction & Property, Other Construction & Property, Western Asia, Asia, Continents, Eastern Mediterranean, Israel, Levant, Republics

The "Construction in Israel - Key Trends and Opportunities to 2025 (H1 2021)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Construction in Israel - Key Trends and Opportunities to 2025 (H1 2021)" report has been added to ResearchAndMarkets.com's offering.
  • Israel's construction industry is forecast to recover by 3.5% in 2021, after contracting by an estimated 8.9% in 2020.
  • Historical (2016-2020) and forecast (2021-2025) valuations of the construction industry in Israel, featuring details of key growth drivers.
  • Analysis of the mega-project pipeline, including breakdowns by development stage across all sectors, and projected spending on projects in the existing pipeline.

BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health

Retrieved on: 
Wednesday, June 16, 2021
Western Asia, Asia, Continents, Eastern Mediterranean, Israel, Levant, Republics, Palestinian National Authority, Forodesine

The Israeli Ministry of Health also has granted an accelerated review.

Key Points: 
  • The Israeli Ministry of Health also has granted an accelerated review.
  • Neopharm is the right partner to help us commercialize in Israel as we continue to bring oral, once-daily ORLADEYO to HAE patients around the world.
  • We are proud of our partnership with BioCryst and excited to deliver a new and innovative treatment option to HAE patients in Israel.
  • In addition to exclusive rights to commercialize ORLADEYO in Israel, Neopharm Israel has exclusive rights to commercialize in the Palestinian Authority.

EASO publishes a COI report: Syria – Situation of returnees from abroad

Retrieved on: 
Friday, June 11, 2021
Western Asia, Continents, Asia, Eastern Mediterranean, Levant, Syria, European Asylum Support Office

Today, the European Asylum Support Office (EASO) published a Country of Origin Information (COI) report titled "Syria: Situation of returnees from abroad".

Key Points: 
  • Today, the European Asylum Support Office (EASO) published a Country of Origin Information (COI) report titled "Syria: Situation of returnees from abroad".
  • This report is part of a series of Syria COI reports produced in 2021.
  • The reports provide information relevant for international protection status determination for Syrian applicants, and in particular for use in updating EASOs country guidance development on Syria.
  • The report, EASO COI Report: Syria Situation of returnees from abroad, focuses on a number of topics relating to the issue of return of Syrians from Europe and Syrias neighbouring countries (Turkey, Lebanon and Jordan) to government-held Syria, including the consequences of having exited Syria illegally and having applied for asylum abroad, the return procedures for Syrian citizens who live outside Syria, potential obstacles to return, and possible treatment upon return in government-held Syria.

Investment in Israeli Innovation Companies Hits $10.5 Billion, Shattering 2020 Record in Under Six Months

Retrieved on: 
Thursday, June 10, 2021
Western Asia, Articles, Asia, Entrepreneurship, Private equity, Eastern Mediterranean, Israel, Levant, Innovation, Startup company

In doing so it matched the total raised throughout the whole of 2020, which was itself a record year, in less than half the time.

Key Points: 
  • In doing so it matched the total raised throughout the whole of 2020, which was itself a record year, in less than half the time.
  • The marked increase in investments in Israeli tech companies (most of which originate from foreign investors) is even more pronounced when compared with investment performance worldwide.
  • While Israel recorded an increase of 137% for the first five months of 2021 compared to the first five months of 2020 (according to Start-Up Nation Finder), the increase globallywas only 89%.
  • This Innovation Business Platform is a comprehensive knowledge hub on Israeli startups, investors, acceleration hubs, multinational corporations, and technology-based innovation associated with academic research.